Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Ultra-hypofractionated 5-fraction radiation therapy for early breast cancer into whole breast and regional nodes: experience in a tertiary hospital.
Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPost-surgery radiotherapy to the breast and regional lymph nodes decreases locoregional tumour recurrence and related mortality. The FAST-Forward approach, with 5 daily fractions, shows non-inferiority to the conventional 15-fraction scheme with similar safety. Authors suggest Simultaneous Integrated Boost (SIB) for the tumour bed and regional nodal irradiation (RNI) for comparable toxicity. OBJECTIVES AND PURPOSES: To describe acute and delayed toxicity in adjuvant radiotherapy patients using FAST-Forward scheme with SIB and analyze associations with patient characteristics. MATERIALS AND
methodsAn observational, descriptive, retrospective study on 120 early breast cancer patients (pT1-3, pN0-1, M0), treated with surgery and adjuvant radiotherapy using the FAST-Forward scheme with SIB at our center. Some also received RNI. Study conducted from June 2021 to October 2023.
resultsMedian age: 55 years (range 30-86). Main histological type: infiltrating ductal carcinoma (80%), with Luminal A as predominant molecular subtype (58.5%). Stage IA tumours (61%), pT1c (40%), G2 (50%). Treatment included: neoadjuvant chemotherapy (18.3%), adjuvant chemotherapy (23.5%), hormonal treatment (82.5%), surgery (99%). Radiotherapy with SIB in 90% of conservative surgeries with a median dose 30 Gy (range: 29-33.6). There was no significant association between acute/chronic toxicity and SIB found. However, there was increased risk of acute induration with neoadjuvant chemotherapy. Adjuvant chemotherapy was linked to significant rates of acute and delayed hyperpigmentation. The acute toxicity in first 6 months post-radiotherapy was only G1. The most frequent late toxicities were G1 indurations, edema, hyperpigmentation.
conclusionsThe FAST-Forward scheme with SIB and RNI in 5 daily fractions seems well-tolerated without severe acute or delayed toxicity.
Indexed as
Identifiers
39680268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.